A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Yoh, Kiyotaka; Hosomi, Yukio; Kasahara, Kazuo; Yamada, Kazuhiko; Takahashi, Toshiaki; Yamamoto, Nobuyuki; Nishio, Makoto; Ohe, Yuichiro; Koue, Toshiko; Nakamura, Takashi; Enatsu, Sotaro; Lee, Pablo; Ferry, David; Tamura, Tomohide; Nakagawa, Kazuhiko

doi:10.1016/j.lungcan.2016.07.019

Public

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Shared by NobleBlocks on Jul 19, 2016 • 12:00 AM UTC

Authors:

Kiyotaka Yoh

Yukio Hosomi

Kazuo Kasahara

Abstract

OBJECTIVES: Ramucirumab plus docetaxel prolongs survival in patients with non-small cell lung cancer (NSCLC) with disease progression after platinum-based therapy. This phase II, double-blind, randomized, placebo-controlled study assessed efficacy and safety of second-line ramucirumab-docetaxel in J...

Subject

Ramucirumab

Docetaxel

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!